FindMyKOL
Clinical trialNCT00118209CompletedPhase 3Interventional

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00118209 is a phase 3 interventional trial sponsored by Alliance for Clinical Trials in Oncology. As of 21 Nov 2026, it is completed. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 4 more drugs in Large B Cell Lymphoma. The registry lists an enrollment of 524 participants at 47 sites in 1 country. The registry lists a start date of 31 May 2005 and a primary completion date of 31 Oct 2017. 2 of its registered investigators have a FindMyKOL profile.

SponsorAlliance for Clinical Trials in Oncology →Enrollment524Large B Cell Lymphoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00118209
FieldValue
Registry IDNCT00118209
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorAlliance for Clinical Trials in Oncology
Enrollment524
Registered sites47
Countries1
ConditionsLarge B Cell Lymphoma
DrugsCyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Prednisone, Rituximab and Vincristine
Start31 May 2005
Primary completion31 Oct 2017
Study completion15 Nov 2021
Last update posted17 Nov 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab together with combination chemotherapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective when given with rituximab in treating diffuse large B-cell non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States5 sites
  • Rebecca and John Moores Ucsd Cancer Center

    La Jolla

  • Camino Medical Group - Treatment Center

    Mountain View

  • Palo Alto Medical Foundation

    Palo Alto

  • Naval Medical Center - San Diego

    San Diego

  • Saint Helena Hospital

    St. Helena

Connecticut, United States1 site
  • Eastern Connecticut Hematology and Oncology Associates

    Norwich

Delaware, United States1 site
  • Ccop - Christiana Care Health Services

    Newark

Illinois, United States4 sites
  • Creticos Cancer Center at Advocate Illinois Masonic Medical Center

    Chicago

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago

  • University of Illinois Cancer Center

    Chicago

  • Cardinal Bernardin Cancer Center at Loyola University Medical Center

    Maywood

Maryland, United States3 sites
  • Alvin and Lois Lapidus Cancer Institute at Sinai Hospital

    Baltimore

  • Nih - Warren Grant Magnuson Clinical Center

    Bethesda

  • National Naval Medical Center

    Bethesda

Michigan, United States1 site
  • Providence Cancer Institute at Providence Hospital - Southfield Campus

    Southfield

Missouri, United States2 sites
  • Christian Hospital Northeast-Northwest

    St Louis

  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

    St Louis

New Hampshire, United States2 sites
  • New Hampshire Oncology - Hematology, Pa at Payson Center for Cancer Care

    Concord

  • New Hampshire Oncology - Hematology, Pa - Hooksett

    Hooksett

New York, United States3 sites
  • Charles R. Wood Cancer Center at Glens Falls Hospital

    Glens Falls

  • New York Weill Cornell Cancer Center at Cornell University

    New York

  • James P. Wilmot Cancer Center at University of Rochester Medical Center

    Rochester

North Carolina, United States4 sites
  • Presbyterian Cancer Center at Presbyterian Hospital

    Charlotte

  • Kinston Medical Specialists

    Kinston

  • Iredell Memorial Hospital

    Statesville

  • Wake Forest University Comprehensive Cancer Center

    Winston-Salem

North Dakota, United States1 site
  • Altru Cancer Center at Altru Hospital

    Grand Forks

Ohio, United States2 sites
  • Mercy Cancer Center at Mercy Medical Center

    Canton

  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

    Columbus

Pennsylvania, United States6 sites
  • Geisinger Cancer Institute at Geisinger Health

    Danville

  • Easton Regional Cancer Center at Easton Hospital

    Easton

  • Geisinger Hazleton Cancer Center

    Hazleton

  • Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center

    Hershey

  • Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital

    Pittsburgh

  • Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

    Wilkes-Barre

Vermont, United States1 site
  • Mountainview Medical

    Berlin Corners

Virginia, United States1 site
  • Virginia Commonwealth University Massey Cancer Center

    Richmond

Washington, United States1 site
  • Madigan Army Medical Center - Tacoma

    Tacoma

West Virginia, United States1 site
  • Mary Babb Randolph Cancer Center at West Virginia University Hospitals

    Morgantown

Wisconsin, United States8 sites
  • Marshfield Clinic - Marshfield Center

    Marshfield

  • Saint Joseph's Hospital

    Marshfield

  • Marshfield Clinic - Lakeland Center

    Minocqua

  • Ministry Medical Group at Saint Mary's Hospital

    Rhinelander

  • Marshfield Clinic - Indianhead Center

    Rice Lake

  • Marshfield Clinic at Saint Michael's Hospital

    Stevens Point

  • Saint Michael's Hospital Cancer Center

    Stevens Point

  • Marshfield Clinic - Weston Center

    Weston

United States, by state

AlaskaAKMaineMEVermont: 1 siteVT1New Hampshire: 2 sitesNH2Washington: 1 siteWA1MontanaMTNorth Dakota: 1 siteND1MinnesotaMNWisconsin: 8 sitesWI8Michigan: 1 siteMI1New York: 3 sitesNY3MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 4 sitesIL4IndianaINOhio: 2 sitesOH2Pennsylvania: 6 sitesPA6New JerseyNJConnecticut: 1 siteCT1California: 5 sitesCA5NevadaNVWyomingWYNebraskaNEMissouri: 2 sitesMO2KentuckyKYWest Virginia: 1 siteWV1Virginia: 1 siteVA1Maryland: 3 sitesMD3Delaware: 1 siteDE1ArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 4 sitesNC4South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CyclophosphamideDoxorubicinEtoposideFilgrastimPegfilgrastimPrednisoneRituximabVincristine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00118209

Each answer restates registry values shown on this page.

What is NCT00118209?

NCT00118209 is a phase 3 interventional trial sponsored by Alliance for Clinical Trials in Oncology. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 4 more drugs in Large B Cell Lymphoma.

Who leads NCT00118209?

The registry names Andrew D. Zelenetz, MD, PhD (study chair, Memorial Sloan Kettering Cancer Center) and Wyndham H. Wilson, MD, PhD (study chair, National Cancer Institute (NCI)) as overall officials.

Where does NCT00118209 run?

The registry lists 47 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00118209 study?

The registered drug and biological interventions are Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Prednisone, Rituximab and Vincristine.

When did NCT00118209 end?

The registry lists a primary completion date of 31 Oct 2017 and a study completion date of 15 Nov 2021. The sponsor last updated the record on 17 Nov 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.